Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging therapeutics for TNBC, describing both previously approved therapies that are currently being repurposed, as well as new target therapies that may improve patient outcomes. Recent findings Emerging therapies are forthcoming in TNBC's treatment landscape, including new post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates. Combination of different therapies such as AKT/PI3K/mTOR-inhibitors, other immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, and histone deacetylase inhibitors is under clinical investigation. The treatment landscape for TNBC is gradually evolving towards a more personalized approach with promising expectations.

Automated summary

Triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers and is associated with a poor prognosis. Recent emerging therapies such as new post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, and combination therapies are showing promise in improving patient outcomes for TNBC. The treatment landscape for TNBC is evolving towards a more personalized approach with the expectation of better outcomes.